中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2011年
7期
28-30
,共3页
氯沙坦%糖尿病心肌病%脑钠肽%C反应蛋白质
氯沙坦%糖尿病心肌病%腦鈉肽%C反應蛋白質
록사탄%당뇨병심기병%뇌납태%C반응단백질
Losartan%Diabetic cardiomyopathy%Brain natriuretic peptide%C-reactive protein
目的 探讨氯沙坦对糖尿病心肌病患者血浆脑钠肽(BNP)及C反应蛋白(CRP)水平的影响.方法 60例糖尿病患者按照是否合并糖尿病心肌病分为糖尿病对照组(30例)和糖尿病心肌病组(30例),并测定血浆BNP及CRP水平;继将糖尿病心肌病组按照随机数字表法分为常规治疗组(15例)及氯沙坦治疗组(15例),采取相应治疗,12周后检测其心功能及血浆BNP、CRP水平的变化.结果 糖尿病心肌病组患者的BNP、CRP水平分别为(331.27±65.64)ng/L、(26.10±10.13)mg/L,明显高于糖尿病对照组的(76.09±39.14)ng/L、(7.03±2.71)mg/L(P＜0.01);氯沙坦治疗组治疗后的BNP及CRP水平明显低于常规治疗组(P＜0.05),左室射血分数明显高于常规治疗组(P＜0.05),左室舒张末期内径明显低于常规治疗组(P＜0.05).结论 BNP与CRP水平升高能作为临床反映糖尿病心肌病变严重程度的血清学指标,而氯沙坦能降低其水平,并改善心功能,对糖尿病心肌病具有较好的疗效.
目的 探討氯沙坦對糖尿病心肌病患者血漿腦鈉肽(BNP)及C反應蛋白(CRP)水平的影響.方法 60例糖尿病患者按照是否閤併糖尿病心肌病分為糖尿病對照組(30例)和糖尿病心肌病組(30例),併測定血漿BNP及CRP水平;繼將糖尿病心肌病組按照隨機數字錶法分為常規治療組(15例)及氯沙坦治療組(15例),採取相應治療,12週後檢測其心功能及血漿BNP、CRP水平的變化.結果 糖尿病心肌病組患者的BNP、CRP水平分彆為(331.27±65.64)ng/L、(26.10±10.13)mg/L,明顯高于糖尿病對照組的(76.09±39.14)ng/L、(7.03±2.71)mg/L(P＜0.01);氯沙坦治療組治療後的BNP及CRP水平明顯低于常規治療組(P＜0.05),左室射血分數明顯高于常規治療組(P＜0.05),左室舒張末期內徑明顯低于常規治療組(P＜0.05).結論 BNP與CRP水平升高能作為臨床反映糖尿病心肌病變嚴重程度的血清學指標,而氯沙坦能降低其水平,併改善心功能,對糖尿病心肌病具有較好的療效.
목적 탐토록사탄대당뇨병심기병환자혈장뇌납태(BNP)급C반응단백(CRP)수평적영향.방법 60례당뇨병환자안조시부합병당뇨병심기병분위당뇨병대조조(30례)화당뇨병심기병조(30례),병측정혈장BNP급CRP수평;계장당뇨병심기병조안조수궤수자표법분위상규치료조(15례)급록사탄치료조(15례),채취상응치료,12주후검측기심공능급혈장BNP、CRP수평적변화.결과 당뇨병심기병조환자적BNP、CRP수평분별위(331.27±65.64)ng/L、(26.10±10.13)mg/L,명현고우당뇨병대조조적(76.09±39.14)ng/L、(7.03±2.71)mg/L(P＜0.01);록사탄치료조치료후적BNP급CRP수평명현저우상규치료조(P＜0.05),좌실사혈분수명현고우상규치료조(P＜0.05),좌실서장말기내경명현저우상규치료조(P＜0.05).결론 BNP여CRP수평승고능작위림상반영당뇨병심기병변엄중정도적혈청학지표,이록사탄능강저기수평,병개선심공능,대당뇨병심기병구유교호적료효.
Objective To explore the effects oflosartan on brain natriuretic peptide(BNP)and C-reactive protein(CLRP)in diabetic cardiomyopathy patients. Methods Sixty diabetics were divided into diabetic control group(30 cases)and diabetic cardiomyopathy group(30 cases), and the levels of BNP and CRP in plasma were determined. Then, diabetic cardiomyopathy group were divided into conventional treatment group(15 cases)and losartan treatment group(15 cases)by random digits table to take corresponding treatment for 12 weeks. The changes of cardiac function, the levels of BNP and CRP in plasma were detected and compared. Results The levels of BNP and CRP in diabetic cardiomyopathy group [(331.27 ±65.64)ng/L,(26.10±10.13)mg/L]were significantly higher than those in diabetic control group[(76.09±39.14)ng/L,(7.03±2.71)mg/L](P＜0.01). After treatment 12 weeks, the levels of BNP and CRP were significantly lower, left ventricular ejection fraction was significantly higher and left ventricular end-diastolic diameter was significantly lower in losartan treatment group than those in conventional treatment group(P＜0.05).Conclusions The increasing levels of BNP and CRP can reflect clinical severity of diabetic cardiomyopathy.Losartan can decrease the levels of BNP and CRP, and improve heart function, and it has better effective on diabetic cardiomyopathy.
